Benitec Biopharma Inc.

4.64-0.1000-2.11%Vol 254.51K1Y Perf -15.05%
Apr 16th, 2021 16:00 DELAYED
BID4.64 ASK4.75
Open4.94 Previous Close4.74
Pre-Market- After-Market4.55
 - -  -0.09 -1.94%
Target Price
14.00 
Analyst Rating
Strong Buy 1.00
Potential %
201.72 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★★     64.83
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     54.95
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap22.36M 
Earnings Rating
Neutral
Price Range Ratio 52W %
15.51 
Earnings Date
3rd Sep 2019

Today's Price Range

4.504.94

52W Range

2.3017.39

5 Year PE Ratio Range

-57.1083.00

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-6.64%
1 Month
41.46%
3 Months
30.70%
6 Months
58.36%
1 Year
-15.05%
3 Years
-90.54%
5 Years
-82.22%
10 Years
-

TickerPriceChg.Chg.%
BNTC4.64-0.1000-2.11
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
18.00
18.50
0.01
0.02
-739.10
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
-386.10
-25 469.80
-24 567.40
-3 338.60
-
RevenueValueIndustryS&P 500US Markets
-7 000.00
0.00
-16.16
-13.06
Earnings HistoryEstimateReportedSurprise %
Q02 2021--0.76-
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
6/2021 FY-3.440.00-
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume254.51K
Shares Outstanding4.82M
Trades Count1.33K
Dollar Volume1.80M
Avg. Volume2.44M
Avg. Weekly Volume355.09K
Avg. Monthly Volume7.75M
Avg. Quarterly Volume2.80M

Benitec Biopharma Inc. (NASDAQ: BNTC) stock closed at 4.64 per share at the end of the most recent trading day (a -2.11% change compared to the prior day closing price) with a volume of 254.76K shares and market capitalization of 22.36M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 14 people. Benitec Biopharma Inc. CEO is Jerel A. Banks.

The one-year performance of Benitec Biopharma Inc. stock is -15.05%, while year-to-date (YTD) performance is 54.67%. BNTC stock has a five-year performance of -82.22%. Its 52-week range is between 2.3 and 17.39, which gives BNTC stock a 52-week price range ratio of 15.51%

Benitec Biopharma Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 1.62, a price-to-sale (PS) ratio of -3 338.22, a price to cashflow ratio of 2.80, a PEG ratio of 2.32, a ROA of -53.86%, a ROC of -73.69% and a ROE of -57.48%. The company’s profit margin is -%, its EBITDA margin is -24 567.40%, and its revenue ttm is $-7 000.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Benitec Biopharma Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Benitec Biopharma Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Benitec Biopharma Inc. is Strong Buy (1), with a target price of $14, which is +201.72% compared to the current price. The earnings rating for Benitec Biopharma Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Benitec Biopharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Benitec Biopharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 24.67, ATR14 : 0.48, CCI20 : -34.43, Chaikin Money Flow : 0.40, MACD : 0.14, Money Flow Index : 64.18, ROC : 7.91, RSI : 38.05, STOCH (14,3) : 30.23, STOCH RSI : 0.28, UO : 52.69, Williams %R : -69.77), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Benitec Biopharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
0 (0.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
Summary RatingStrong Buy
1.00
Strong Buy
1.00
-

Benitec Biopharma Inc.

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV).

CEO: Jerel A. Banks

Telephone: +1 510 780-0819

Address: 3940 Trust Way, Hayward 94545, CA, US

Number of employees: 14

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

65%35%

Bearish Bullish

53%47%

News

Stocktwits